|
|
|||
|
Date: Thursday, November 29, 2012 - 8:30 am
|
||
|
|||
![]() Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculties unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.
Benefits of attending include: Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors Review clinical results from the DEMAND study Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies Evaluate new targets to reduce hypertension, hyperkalaemia and endothelial inflammation Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments
Key speakers include: Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes Division, Sanofi-Aventis Hans-Jürgen Wörle, Vice President & Therapeutic Area Head Metabolism, Clinical Development and Medical Affairs, Boehringer-Ingelheim James F. List, Vice President, Full Development, Bristol-Myers Squibb Martin Simán, Director, Design and Interpretation Centre of Excellence, AstraZeneca Phil Ambery, Medical Director, Cardiovascular and Metabolic R&D, GlaxoSmithKline Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical Products Division, Baxter Healthcare |
|||
|
||
Home | Calendar of Events | Services | News | Resources | Products | Contact | Directory Search | Partner with Us | Media Partners | Link to Us | Terms of Use |
© 2019 Bioscreening.com